ASCO 2026 - with Dr. Christine Brezden-Masley: OPTIMA

Dr. Christine Brezden-Masley reviews the ASCO 2026 OPTIMA trial, highlighting how Prosigna-guided treatment identified many high-risk ER-positive, HER2-negative patients who may safely avoid chemotherapy while achieving excellent outcomes.